TrimRx vs Medvi: Complete 2026 Comparison

Introduction

TrimRx and Medvi both operate in the compounded GLP-1 telehealth space, but their programs and pricing structures differ in detail. This comparison works through what each platform actually does, where they overlap, and where the practical differences sit for patients deciding between them.

The data points pull from each platform’s site, trial evidence underpinning the medications, and broader industry reporting on telehealth GLP-1 prescribing in 2025-2026.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Does Each Platform Actually Do?

TrimRx is a GLP-1 weight loss telehealth platform. It prescribes compounded semaglutide and tirzepatide, ships medication monthly from licensed compounding pharmacies, and provides clinical care through an in-house clinician team. Programs are designed for 12 to 24 month treatment timelines.

Quick Answer: Both platforms prescribe compounded semaglutide and tirzepatide for weight loss

Medvi operates as a telehealth platform with weight loss as a primary product area. It prescribes compounded semaglutide and tirzepatide with a similar monthly program structure.

The category convergence in 2024-2025 reflects strong patient demand for compounded GLP-1 options. The American Society of Health-System Pharmacists tracked the growth of telehealth-led compounded prescribing as a significant industry trend.

How Do the Medication Options Compare?

Both platforms prescribe compounded semaglutide and compounded tirzepatide as their core GLP-1 offerings. The active molecules are the same as in Ozempic®, Wegovy®, Mounjaro®, and Zepbound®, prepared by 503A or 503B pharmacies.

The compounded route bypasses the supply and pricing constraints of branded medications. The FDA noted in October 2024 that semaglutide was removed from its drug shortage list, which affected 503A compounding rules for that molecule. Tirzepatide remained in a transitional period.

Both platforms operate within current regulatory constraints. Compounded medication remains legal when prepared for an individual patient with valid clinical indication.

What Does Pricing Look Like at Each?

TrimRx publishes compounded semaglutide programs at roughly $200 to $300 monthly. Compounded tirzepatide runs $300 to $400. Pricing is set at the platform level and visible before commitment. The free assessment quiz is the entry point.

Medvi prices fall in similar ranges depending on dose and program. Specific pricing tiers vary, and both platforms occasionally run promotional offers for new patients.

For uninsured patients, the compounded route at either platform represents major savings over branded retail. Branded Wegovy at cash retail is roughly $1,349 monthly; branded Zepbound is around $1,060 through manufacturer DTC or higher at retail.

How Does the Provider Experience Compare?

TrimRx assigns a clinician from its in-house team after intake review. Communication runs through a patient portal with messaging, refill workflows, and dose adjustment forms. The structure is async-first.

Medvi operates a similar telehealth model with clinical team support through messaging and portal-based workflows. Both platforms prioritize structured dose titration and ongoing patient support.

For specific clinician availability or response time differences, individual reviews vary. A 2024 JD Power telehealth study found patient satisfaction tracks closely with provider responsiveness across platforms.

What About State Licensing Coverage?

Both platforms operate in most US states. State availability shifts as licensing expands. Each platform’s site lists current coverage at intake.

If your state isn’t covered by one platform but is by the other, that’s an immediate tiebreaker. Check both sites’ current state lists before completing an intake.

How Does Shipping Work?

Both platforms ship compounded medication directly to patients in cold-chain packaging. Standard timing is 3 to 7 days after clinical approval. First shipments from intake typically arrive in 7 to 14 days.

Holiday seasons and weather events affect both. Shipping reliability is a review-level detail where individual experiences vary.

What About Insurance Handling?

Neither platform bills insurance directly. Both operate on cash-pay models for compounded medications. HSA and FSA cards are generally accepted for eligible expenses.

For patients with strong commercial insurance coverage of branded Wegovy or Zepbound, the compounded route at either platform may be more expensive than a branded prescription with insurance at retail pharmacy. The cash-pay model is built for uninsured or underinsured patients.

KFF Health News reporting through 2024-2025 documented continued utilization management on commercial GLP-1 coverage for weight loss indications.

Key Takeaway: STEP 1 (Wilding et al. 2021 NEJM) showed 14.9% weight loss with semaglutide; SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9% with tirzepatide

How Do Safety and Oversight Compare?

Both platforms use US-licensed clinicians and 503A or 503B compounding pharmacies. 503B outsourcing facilities are inspected by the FDA. 503A pharmacies are regulated at the state board level.

A 2023 JAMA Network Open analysis (Anderson et al.) showed telehealth GLP-1 prescribing produces clinical outcomes comparable to in-person care when structured titration and adherence support are in place.

Both platforms follow standard contraindication screening and ongoing patient monitoring protocols within their respective clinical workflows.

How Do Side Effect Support and Follow-up Compare?

Both platforms support patients through dose titration with side effect coaching. Common GLP-1 side effects include nausea, constipation, fatigue at dose changes, and occasional injection site reactions.

The STEP 1 and SUSTAIN trials documented gastrointestinal effects as the leading adverse event category. Structured dose escalation, dietary counseling, and as-needed dose holds are standard. Both platforms apply this through their clinical workflows.

Patient-reported tolerance through the portal lets the clinician adjust pace. Reviews suggest both platforms are responsive on this, though individual experiences vary.

Where Does Each Platform Tend to Win?

TrimRx’s strengths include the free assessment quiz, predictable program pricing, and program-level continuity through the clinician team. Patients on a 12 to 24 month treatment timeline often find the structure appealing.

Medvi’s strengths include similar pricing competitiveness and clinical model. Specific tiebreakers come down to state licensing, current pricing offers, and individual clinical experience.

For prospective patients, completing the assessment process at both platforms to compare specific personalized treatment plans is the most concrete way to decide.

What Does the Broader GLP-1 Evidence Base Show?

Beyond platform specifics, the underlying evidence for GLP-1 therapy is substantial. The STEP program (Wilding et al. 2021 NEJM and follow-up trials) established semaglutide 2.4 mg as effective for weight loss with 14.9% mean reduction at 68 weeks. The SURMOUNT program (Jastreboff et al. 2022 NEJM) showed tirzepatide 15 mg achieving 20.9% reduction at 72 weeks.

Cardiovascular outcomes data adds context. SELECT (Lincoff et al. 2023 NEJM) showed a 20% reduction in major adverse cardiovascular events with semaglutide in patients with obesity and preexisting cardiovascular disease. FLOW (Perkovic et al. 2024 NEJM) demonstrated kidney and cardiovascular benefits in chronic kidney disease patients with type 2 diabetes.

The molecule is what drives outcomes. Platform choice affects access, cost, and support, but not the fundamental pharmacology.

How Do Platform-level Outcomes Track Drug-level Evidence?

Patient-reported outcomes on telehealth platforms often track the trial data when adherence holds and doses reach maintenance. A 2023 JAMA Network Open analysis (Anderson et al.) found telehealth GLP-1 prescribing produced clinical outcomes comparable to in-person care under structured titration protocols.

Real-world weight loss commonly varies more than trial-population weight loss because adherence is less controlled. Patients who reach maintenance dose and stay on therapy for 12 or more months tend to approach trial-level outcomes. Patients who drop out during titration see smaller effects.

This pattern holds across platforms. The structural differences between providers affect access and cost more than they affect clinical outcomes when the same molecule is delivered at the same dose.

What Should You Check Before Committing to Either Platform?

Three practical checks before signing up. First, state licensing: confirm the platform you want is licensed in your state. Coverage shifts as licensing expands. Second, current pricing: compare the personalized treatment plan output from each platform’s free assessment quiz. Promotional rates shift over time. Third, your insurance situation: if you have strong commercial coverage of branded GLP-1s, the math may favor a branded prescription with insurance applied at a retail pharmacy over either platform.

The 2024 American Gastroenterological Association obesity pharmacotherapy guideline continues to support GLP-1 receptor agonists as first-line agents for chronic obesity management. The clinical case is established; the choice of access path is where patients differentiate.

Bottom line: State availability and current promotional pricing are common tiebreakers

FAQ

Are TrimRx and Medvi Essentially the Same?

They occupy the same category and prescribe similar compounded GLP-1 products. Specific differences come down to state licensing, exact pricing tier, customer support experience, and individual clinical workflows. Category-level similarity is real.

Do Both Prescribe Compounded Tirzepatide?

Yes, both platforms include compounded tirzepatide as a core product. Specific dose availability depends on clinical review and the compounding pharmacy partnership.

Which Is Cheaper, TrimRx or Medvi?

Pricing at both platforms typically lands in the $200 to $400 monthly range for compounded GLP-1s. The cheaper option for an individual patient depends on the specific medication, dose, and any current promotions. Check both at intake.

Can I Switch Between Them Mid-treatment?

Yes. Switching telehealth providers for a non-controlled medication doesn’t require formal transfer paperwork. Time the switch to avoid medication gaps, ideally with 7 to 14 days of supply remaining.

Do Either Accept Insurance?

Neither bills insurance directly. Both operate on cash-pay structures for compounded medications. HSA and FSA cards are generally accepted.

Which Has Better State Coverage?

Both operate in most states with some exclusions that shift as licensing expands. Check each platform’s current state list at signup.

How Quickly Does Each Ship the First Shipment?

Both target 7 to 14 days from intake submission to first delivery. Clinical review takes 24 to 48 hours, and the compounding pharmacy ships within 3 to 7 days after approval.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.